ARIA
Library/metabolic/AOD-9604

AOD-9604

Not FDA Approved✓ WADA Permitted

Anti-Obesity Drug-9604 / Modified GH fragment (176-191)

metabolic◆EmergingModified human growth hormone fragment (hGH 176-191)

Modified fragment of hGH amino acids 176-191. Developed as a lipolytic agent mimicking GH's fat-metabolizing effects without affecting blood glucose or IGF-1. Phase 2 trials showed modest weight loss. Abandoned by developer but remains available in peptide form.

Confidence
45%
Half-Life ~30-60 minutes
Cost ~$350/mo
Quick Reference
Routesubcutaneous
MechanismMimics the lipolytic domain of GH without the diabetogenic region. Stimulates li...
SequenceTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Mol. Weight1319.58 Da
Reviewed2026-08-08

Mechanism of Action

Mimics the lipolytic domain of GH without the diabetogenic region. Stimulates lipolysis in adipocytes via beta-3 adrenergic pathway. Inhibits lipogenesis (reduces phospholipid synthesis and LDL uptake). Does NOT bind GH receptor → no effect on IGF-1, glucose, or growth. Enhancements: modified with lysine chain for stability.

Dosing Protocol

250-500μg SC daily, preferably in the morning on empty stomach. Courses of 4-12 weeks. Primarily for targeted lipolysis/fat loss.

Key Studies

2007

AOD-9604 Phase 2 obesity trial

PMID 16939857clinical_trial
2003

AOD-9604 lipolytic mechanism in adipocytes

PMID 12589934preclinical
2012

AOD-9604 chondroprotective effects

PMID 22503079preclinical

Adverse Effects

Generally well toleratedInjection site reactionsMild headacheNo significant effect on glucose or IGF-1Nausea (rare)

Contraindications

  • Pregnancy
  • Active malignancy (theoretical caution)
  • Breastfeeding

Storage

Lyophilized: 2-8°C. Reconstituted: 2-8°C, use within 30 days. Protect from light.

Clinical Applications

  • ["weight_management"
  • "fat_loss"
  • "metabolic_optimization"]